The Beatrice Hunter Cancer Research Institute logo
  • Dr. Ravi Ramjeesingh, MD, PhD, FRCPC

Appointments:

Associate Professor Division of Medical Oncology, Department of Medicine
Associate Professor Department of Community Health and Epidemiology
Staff Medical Oncologist, Nova Scotia Cancer Center
Chair of the HPB (Hepatopancreobiliary) Cancer Disease Site

Affiliations:

Dalhousie University, NSHA

Research Interests:

Gastrointestinal Cancers, Pancreatic Cancer, Cholangiocarcinomas, Hepatocellular Carcinoma, Precision Medicine, Real World Evidence

The focus of my research has been primarily pancreatic and hepatobiliary tumors. As a medical oncologist and lead for the HPB Cancer disease site, I am involved in several industry and academic clinical trials as the lead investigator. My focus is on creating a provincial pancreatic cancer database and associated tumor bank. As the lead investigator of The PANcreatic Cancer Research platform to Examine biomarkers And Systemic treatment outcomes (PANCREAS) project, I am working with other investigators to tackle the questions about referral patterns, and patient outcomes in the province and begin to investigate biomarkers for pancreatic cancer.

What brought you to your current institution?

My family fell in love with Nova Scotia on our multiple vacations here and when the opportunity presented itself to become a medical oncologist in Halifax, I jumped at the chance.

Hometown: Mississauga, Ontario

Learn more about my research: medicine.dal.ca/departments/department-sites/medicine/divisions/medical-oncology/our-people/faculty/ravi-ramjeesingh.html

Involvement with BHCRI to date:

I am an Associate member. I have participated in BHCRI’s Seminar Series as an invited speaker.

Phone:

902 473 6106

Contact:

Bethune Building, QEII Health Sciences Centre, 1276 South Park Street, Halifax, Nova Scotia, Canada B3H 2Y9

Publications:

Graham C, Orr C, Bricks CS, Hopman WM, Hammad N, Ramjeesingh R. A retrospective analysis of the role of proton pump inhibitors on colorectal cancer disease survival. Curr Oncol 2016 Dec;23(6):e583-e588.

Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, Davey S. Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma. Curr Oncol 2016 June;23(3):e171-e178.

Ramjeesingh R, Orr C, Bricks CS, Hopman WM, Hammad N. A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol 2016 Apr;23(2):e116-122. 

Ramjeesingh R, Meyer RM, Brouwers M, Booth CM. Alignment of practice guidelines with targeted therapy drug funding policies in Ontario. Curr Oncol 2013 Feb;20(1):e21-33.

Site by: Spectacle Group